Qiagen NV has two FDA-approved companion diagnostics on the market and a broad portfolio of similar projects in development, which are considered important potential growth drivers for the German diagnostics developer. Upcoming Medicare reimbursement changes could pave the way for more value being recognized for FDA-approved validated tests and further improve the market opportunity, Chief Medical Officer Tadd Lazarus indicated during an investor day presentation Nov. 18.
The changes Lazarus referred to are being implemented in the Medicare space by administrative claims contractor Palmetto GBA LLC with its molecular diagnostic reimbursement initiative, or MolDx. The initiative involves...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?